FDA 483 - BIOGEN, INC - October 20, 2026

An FDA inspection of BIOGEN, INC in Cambridge, MA, revealed two significant observations. The firm failed to adequately monitor an IND investigation, specifically regarding the trustworthiness and reliability of electronic records and audit trails. Additionally, the inspection found that the sponsor did not obtain sufficient financial disclosure information from clinical investigators for multiple studies.